^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SMYD3 inhibitor

    i
    Other names: SMYD3 inhibitor
    Associations

    News

    Trials
    Company:
    GSK, Stanford University
    Drug class:
    SMYD3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck. (PubMed, Cell Rep)
    SMYD3 overexpression is associated with decreased CD8 T cell infiltration and poor response to neoadjuvant pembrolizumab. These data support combining SMYD3 depletion strategies with checkpoint blockade to overcome anti-PD-1 resistance in HPV-negative HNSCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • DNMT1 (DNA methyltransferase 1) • SMYD3 (SET And MYND Domain Containing 3) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1)
    |
    SMYD3 overexpression
    |
    Keytruda (pembrolizumab) • SMYD3 inhibitor